30/07/2026
Melisa is among the first young women in Eswatini to receive lenacapavir (LEN), a twice-yearly injectable form of pre-exposure prophylaxis (PrEP) that is nearly 100% effective at preventing HIV.
For adolescent girls and young women – who account for nearly a quarter of new HIV infections in sub-Saharan Africa – LEN could be a game-changer.
In less than a year after regulatory approval, The Global Fund and partners have delivered LEN to 10 of the world’s highest HIV-burden countries, with 24 countries expected to receive it by the end of the year.
At the 26th International AIDS Conference, Melisa’s story highlights a turning point in global health equity. For the first time, a major HIV prevention innovation is being introduced in both high- and low-income countries at the same time – closing a gap that once cost millions of lives.
Read more: https://globalfund.exposure.co/in-eswatini-an-hiv-breakthrough-delivered